Biosimilars in IBD – what patients need to know

In 2016 the US Food and Drug administration approved two biosimilar products which will be used in the treatment of inflammatory bowel disease in the near future. The FDA has approved Inflectra, a biosimilar to Janssen’s Remicade (infliximab) and Amjevita, a biosimilar to Abbvie’s Humira (adalimumab). What is a biosimilar? The FDA defines a biosimilar …

Continue reading Biosimilars in IBD – what patients need to know